NYSE:TEVAPharmaceuticals
Why Is Teva (TEVA) Buying A Neuroscience Asset Through Bankruptcy Court?
Teva Pharmaceutical Industries (NYSE:TEVA) agreed to acquire a neuroscience asset from BioXcel Therapeutics involving a sublingual film for agitation in schizophrenia and bipolar disorder patients through a court supervised bankruptcy sale.
The product is under FDA review, and the transaction remains subject to court approval as of late August 2026.
The deal aligns with Teva's stated Pivot to Growth strategy and adds to its focus on neuroscience treatments.
For readers looking to explore...